Several Levilactobacillus brevis strains have the potential to be used as
probiotics since they provide health benefits due to the interaction of live
cells, and of their secreted products, with the host (tissues). Therefore, the
development of simple fermentation processes that improve cell viability to
reduce industrial production costs, and at the same time the characterization
and biological evaluation of cell-free postbiotics that can further promote
application, are of great interest. In the present study, small scale batch
fermentations on semi defined media, deprived of animal derived raw
materials, were used to optimize growth of L. brevis SP48, reaching 1.2 ±
0.4 × 1010 CFU/ml of viable cells after 16 h of growth. Displacement,
competition, and inhibition assays compared the effect, on Helicobacter
pylori, of L. brevis cells to that of its partially purified potentially postbiotic
fraction rich in exopolysaccharides and proteins. The expression of pro and
anti-inflammatory biochemical markers indicated that both samples activated
antimicrobial defenses and innate immunity in a gastric model. Moreover, these
compounds also acted as modulators of the inflammatory response in a gut
in vitro model. These data demonstrate that the high molecular weight
compounds secreted by L. brevis SP48 can contrast H. pylori and reduce
inflammation related to intestinal bowel disease, potentially overcoming
issues related to the preservation of probiotic viability.

Title

Frontiers in Bioengineering and Biotechnology

Publisher

Frontiers

Publisher Country

Switzerland

Publication Type

Prtinted only

Volume

10

Year

2022

Pages

22-32